Efficient cross-priming of antiviral CD8+ T cells by antigen donor cells is GRP94 independent

Journal of Immunology

Volumn 183, Issue 7, 2009, Pages 4205-4210

  Lev, Avital ^a   Dimberu, Peniel ^a   Das, Suman R ^a   Maynard, Jason C ^b   Nicchitta, Christopher V ^b   Bennink, Jack R ^a   Yewdell, Jonathan W ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE REGULATED PROTEIN 94; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SMALL INTERFERING RNA; ANTIVIRUS AGENT; ENDOPLASMIN; H 2KB PROTEIN, MOUSE; H-2KB PROTEIN, MOUSE; H2 ANTIGEN; MEMBRANE PROTEIN; PEPTIDE FRAGMENT; VIRUS ANTIGEN;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PRESENTATION; GENE SILENCING; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STABLE TRANSFECTION; VIRUS INFECTION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL LINE; COMPARATIVE STUDY; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; INFLUENZA VIRUS A; METABOLISM; PHYSIOLOGY; TRANSGENIC MOUSE; TRANSPLANTATION; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS; VIROLOGY;

ANIMALS; ANTIGENS, VIRAL; ANTIVIRAL AGENTS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CROSS-PRIMING; FEMALE; GENE KNOCKDOWN TECHNIQUES; H-2 ANTIGENS; HUMANS; INFLUENZA A VIRUS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; RNA, SMALL INTERFERING; VACCINIA VIRUS; VESICULAR STOMATITIS INDIANA VIRUS;

EID: 70449719355     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0901828     Document Type: Article

References (48)

1. Steinman, R. M. 2007. Dendritic cells: understanding immunogenicity. Eur. J. Immunol. 37(Suppl. 1): S53-S60.
2. + T cells in vivo: the key to rational vaccine design. Annu. Rev. Immunol. 23: 651-682.
3. Yewdell, J. W. 2007. Plumbing the sources of endogenous MHC class I peptide ligands. Curr. Opin. Immunol. 19: 79-86.
4. Shen, L., and K. L. Rock. 2004. Cellular protein is the source of cross-priming antigen in vivo. Proc. Natl. Acad. Sci. USA 101: 3035-3040.
5. + T cell cross-priming via transfer of proteasome substrates. Science 304: 1318-1321.
6. Wolkers, M. C., N. Brouwenstijn, A. H. Bakker, M. Toebes, and T. N. Schumacher. 2004. Antigen bias in T cell cross-priming. Science 304: 1314-1317.
7. Basta, S., R. Stoessel, M. Basler, M. van den Broek, and M. Groettrup. 2005. Cross-presentation of the long-lived lymphocytic choriomeningitis virus nucleo-protein does not require neosynthesis and is enhanced via heat shock proteins. J. Immunol. 175: 796-805.
8. + T cells. Nat. Immunol. 6: 593-599.
9. Murshid, A., J. Gong, and S. K. Calderwood. 2008. Heat-shock proteins in cancer vaccines: agents of antigen cross-presentation. Expert Rev. Vaccines 7: 1019-1030.
10. Berwin, B., M. F. Rosser, K. G. Brinker, and C. V. Nicchitta. 2002. Transfer of GRP94(Gp96)-associated peptides onto endosomal MHC class I molecules. Traf- fic 3: 358-366.
11. Randow, F., and B. Seed. 2001. Endoplasmic reticulum chaperone gp96 is required for innate immunity but not cell viability. Nat. Cell Biol. 3: 891-896.
12. Melnick, J., J. Dul, and Y. Argon. 1994. Sequential interaction of the chaperones BiP and GRP94 with immunoglobulin chains in the endoplasmic reticulum Nature 370: 373-375.
13. Yang, Y., B. Liu, J. Dai, P. K. Srivastava, D. J. Zammit, L. Lefrançois, and Z. Li. 2007. Heat shock protein gp96 is a master chaperone for Toll-like receptors and is important in the innate function of macrophages. Immunity 26: 215-226.
14. Dollins, D., J. Warren, R. Immormino, and D. Gewirth. 2007. Structures of GRP94-nucleotide complexes reveal mechanistic differences between the hsp90 chaperones. Mol. Cell 28: 41-56.
15. Berwin, B., J. Hart, S. Rice, S. Gass, S. Pizzo, S. Post, and C. Nicchitta. 2003. Scavenger receptor-A mediates gp96/GRP94 and calreticulin internalization by antigen-presenting cells. EMBO J. 22: 6127-6136.
16. Tewalt, E. F., J. C. Maynard, J. J. Walters, A. M. Schell, B. L. Berwin, C. V. Nicchitta, and C. C. Norbury. 2008. Redundancy renders the glycoprotein 96 receptor scavenger receptor A dispensable for cross priming in vivo. Immunology 125: 480-491.
17. Suto, R., and P. K. Srivastava. 1995. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 269: 1585-1588.
18. + cells. J. Immunol. 165: 2582-2587.
19. Wallin, R. P., A. Lundqvist, S. H. More, A. von Bonin, R. Kiessling, and H. G. Ljunggren. 2002. Heat-shock proteins as activators of the innate immune system. Trends Immunol. 23: 130-135.
20. Demine, R., and P. Walden. 2005. Testing the role of gp96 as peptide chaperone in antigen processing. J. Biol. Chem. 280: 17573-17578. (Pubitemid 41388990)
21. Tsan, M.-F., and B. Gao. 2004. Cytokine function of heat shock proteins. Am. J. Physiol. 286: C739-C744.
22. Nicchitta, C. V., D. M. Carrick, and J. C. Baker-Lepain. 2004. The messenger and the message: gp96 (GRP94)-peptide interactions in cellular immunity. Cell Stress Chaperones 9: 325-331.
23. 2+. FEBS J. 273: 513-522.
24. Javid, B., P. A. MacAry, and P. J. Lehner. 2007. Structure and function: heat shock proteins and adaptive immunity. J. Immunol. 179: 2035-2040.
25. Demine, R., and P. Walden. 2005. Testing the role of gp96 as peptide chaperone in antigen processing. J. Biol. Chem. 280: 17573-17578. (Pubitemid 41388990)
26. Testori, A., J. Richards, E. Whitman, G. Mann, J. Lutzky, L. Camacho, G. Parmiani, G. Tosti, J. Kirkwood, A. Hoos, et al. 2008. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J. Clin. Oncol. 1: 955-962.
27. Amato, R. J. 2007. Heat-shock protein-peptide complex-96 for the treatment of cancer. Expert Opin. Biol. Ther. 7: 1267-1273.
28. Lev, A., K. Takeda, D. Zanker, J. C. Maynard, P. Dimberu, E. Waffarn, J. Gibbs, N. Netzer, M. F. Princiotta, L. Neckers, et al. 2008. The exception that reinforces the rule: crosspriming by cytosolic peptides that escape degradation. Immunity 28: 787-798.
29. + T cell immunodominance hierarchies when antigen is limiting. J. Immunol. 177: 2917-2925.
30. + T cells by viral and tumor antigens is a robust phenomenon. Eur. J. Immunol. 34: 194-199.
31. Menoret, A., Z. Li, M. L. Niswonger, A. Altmeyer, and P. K. Srivastava. 2001. An endoplasmic reticulum protein implicated in chaperoning peptides to major histocompatibility of class I is an aminopeptidase. J. Biol. Chem. 276: 33313-33318. (Pubitemid 37384537)
32. Srivastava, P. 2002. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu. Rev. Immunol. 20: 395-425. (Pubitemid 34293430)
33. Fruci, D., G. Lauvau, L. Saveanu, M. Amicosante, R. H. Butler, A. Polack, F. Ginhoux, F. Lemonnier, H. Firat, and P. M. van Endert. 2003. Quantifying recruitment of cytosolic peptides for HLA class I presentation: impact of TAP transport. J. Immunol. 170: 2977-2984. (Pubitemid 36302170)
34. Porgador, A., J. W. Yewdell, Y. Deng, J. R. Bennink, and R. N. Germain. 1997. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 6: 715-726. (Pubitemid 27305734)
35. + T cells in vivo: the key to rational vaccine design. Annu. Rev. Immunol. 23: 651-682.
36. Randow, F., and B. Seed. 2001. Endoplasmic reticulum chaperone gp96 is required for innate immunity but not cell viability. Nat. Cell Biol. 3: 891-896.
37. Kurts, C., W. R. Heath, F. R. Carbone, J. Allison, J. F. Miller, and H. Kosaka. 1996. Constitutive class I-restricted exogenous presentation of self antigens in vivo. J. Exp. Med. 184: 923-930. (Pubitemid 26313550)
38. + T cell immunodominance hierarchies when antigen is limiting. J. Immunol. 177: 2917-2925.
39. Shen, L. J., and K. L. Rock. 2004. Cellular protein is the source of cross-priming antigen in vivo. Proc. Natl. Acad. Sci. USA 101: 3035-3040. (Pubitemid 38327730)
40. Falk, K., O. Rötzschke, and H. G. Rammensee. 1990. Cellular peptide composition governed by major histocompatibility complex class I molecules. Nature 348: 248-251. (Pubitemid 20383091)
41. Wood, C., P. Srivastava, R. Bukowski, L. Lacombe, A. I. Gorelov, S. Gorelov, P. Mulders, H. Zielinski, A. Hoos, F. Teofilovici, et al. 2008. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 372: 145-154.
42. Testori, A., J. Richards, E. Whitman, G. B. Mann, J. Lutzky, L. Camacho, G. Parmiani, G. Tosti, J. M. Kirkwood, A. Hoos, et al. 2008. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J. Clin. Oncol. 26: 955-962.
43. Gidalevitz, T., C. Biswas, H. Ding, D. Schneidman-Duhovny, H. J. Wolfson, F. Stevens, S. Radford, and Y. Argon. 2004. Identification of the N-terminal peptide binding site of glucose-regulated protein 94. J. Biol. Chem. 279: 16543-16552.
44. Schreiber, T. H., V. V. Deyev, J. D. Rosenblatt, and E. R. Podack. 2009. Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination. Cancer Res. 69: 2026-2033.
45. Oizumi, S., N. Strbo, S. Pahwa, V. Deyev, and E. R. Podack. 2007. Molecular and cellular requirements for enhanced antigen cross-presentation to CD8 cytotoxic T lymphocytes. J. Immunol. 179: 2310-2317.
46. Dai, J., B. Liu, M. M. Caudill, H. Zheng, Y. Qiao, E. R. Podack, and Z. Li. 2003. Cell surface expression of heat shock protein gp96 enhances cross-presentation of cellular antigens and the generation of tumor-specific T cell memory. Cancer Immun. 3: 1.
47. Yamazaki, K., T. Nguyen, and E. R. Podack. 1999. Cutting edge: tumor secreted heat shock-fusion protein elicits CD8 cells for rejection. J. Immunol. 163: 5178-5182.
48. Srivastava, P. K., and M. Heike. 1991. Tumor-specific immunogenicity of stress-induced proteins: convergence of two evolutionary pathways of antigen presentation? Semin. Immunol. 3: 57-64.